Literature DB >> 11579871

How can we do pharmacokinetic studies in the tropics?

J A Simpson1, L Aarons, N J White.   

Abstract

Information regarding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a drug provides the basis for optimizing dosing. PK-PD information should be obtained from patients representative of the overall target population, but in many tropical hospitals or health care facilities it may be medically hazardous or logistically difficult for an ill patient or a young child to be sampled repeatedly. Traditional methods used to determine the pharmacokinetic properties of a drug require analysis of a large number of blood samples per subject. However, using modern statistical methods, sparse datasets (i.e. with assay results from only a few, or as little as one blood sample per subject) can now be analysed by a method termed 'the population approach'. Modern assay techniques can often be adapted to small blood volumes allowing finger prick blood samples to be taken. One of the major aims of the population approach is to distinguish and characterize patient and disease contributors to inter-individual variance in drug pharmacokinetics. The purpose of this paper is to explain the basis of the population approach, to highlight its advantages compared to traditional methods of analysis, and to review the application of the population approach to data from field studies of antimalarial drugs. The design of population pharmacokinetic studies is also discussed briefly. The principles discussed in the paper are also applicable to pharmacodynamic data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579871     DOI: 10.1016/s0035-9203(01)90178-6

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  10 in total

1.  Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegardh; Anna Annerberg; Joel Tarning; Rose McGready; Lucy Phaiphun; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

2.  Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

Authors:  Julie A Simpson; Dyfrig Hughes; Christine Manyando; Kalifa Bojang; Leon Aarons; Peter Winstanley; Geoffrey Edwards; William A Watkins; Steve Ward
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

3.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett; Harin Karunajeewa; Sean Hewitt; Mey Bouth Denis; Chiv Lim; Doung Socheat
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

4.  Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.

Authors:  George O Adjei; Kim Kristensen; Bamenla Q Goka; Lotte C G Hoegberg; Michael Alifrangis; Onike P Rodrigues; Jorgen A L Kurtzhals
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

Review 5.  Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections.

Authors:  G Edwards; S Krishna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-17       Impact factor: 3.267

Review 6.  Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization.

Authors:  Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

7.  Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.

Authors:  Liusheng Huang; Norah Mwebaza; Richard Kajubi; Florence Marzan; Camilla Forsman; Sunil Parikh; Francesca T Aweeka
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

8.  Towards optimal design of anti-malarial pharmacokinetic studies.

Authors:  Julie A Simpson; Kris M Jamsen; Ric N Price; Nicholas J White; Niklas Lindegardh; Joel Tarning; Stephen B Duffull
Journal:  Malar J       Date:  2009-08-06       Impact factor: 2.979

9.  Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.

Authors:  Katherine Kay; Eva Maria Hodel; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

10.  Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum.

Authors:  Julie A Simpson; Kris M Jamsen; Tim J C Anderson; Sophie Zaloumis; Shalini Nair; Charles Woodrow; Nicholas J White; Francois Nosten; Ric N Price
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.